Literature DB >> 25074706

IL-27 controls sepsis-induced impairment of lung antibacterial host defence.

Ju Cao1, Fang Xu2, Shihui Lin2, Zhixin Song3, Lipin Zhang1, Peng Luo1, Huajian Xu1, Dairong Li4, Ke Zheng5, Guosheng Ren5, Yibing Yin3.   

Abstract

BACKGROUND: Interleukin 27 (IL-27) is an important cytokine regulating host immune responses. However, its role in sepsis-induced immunosuppression remains unclear. AIM: To investigate the role of IL-27 in modulating sepsis-induced immunosuppression using a murine model of caecal ligation and puncture (CLP)-induced sepsis followed by secondary challenge with Pseudomonas aeruginosa.
METHODS: CLP or sham surgery was performed in wild-type (WT) and IL-27 receptor (IL-27R)/WSX-1 knockout (KO) mice, and then mice were infected with intratracheal P aeruginosa.
RESULTS: IL-27 was upregulated in patients with sepsis and septic mice. Following sepsis and secondary intrapulmonary bacterial challenge, IL-27R KO mice had higher survival rates and improved bacterial clearance from lung and blood compared with WT mice, which was associated with early increased pulmonary cytokine/chemokine production, as well as enhanced neutrophil recruitment to airspaces. Neutralisation of IL-27 in septic mice significantly improved survival and clearance of bacteria from the lungs of septic mice infected with P aeruginosa, and direct application of recombinant IL-27 could increase susceptibility to P aeruginosa infection. The resistance of septic IL-27R KO mice to secondary P aeruginosa infection was abrogated by depletion of alveolar macrophages (AMs) and neutrophils. AMs from septic IL-27R KO mice had higher bacterial uptake and killing capacities, enhanced cytokine/chemokine production, and increased expression of costimulatory molecules compared with those from WT mice, while neutrophils from septic IL-27R KO mice had increased bacterial killing ability and higher expression of adhesion molecule Mac-1 compared with WT neutrophils.
CONCLUSIONS: IL-27 is an important mediator of sepsis-induced impairment of lung antibacterial host defence. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Bacterial Infection; Pneumonia; Respiratory Infection

Mesh:

Substances:

Year:  2014        PMID: 25074706     DOI: 10.1136/thoraxjnl-2014-205777

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Interruption of macrophage-derived IL-27(p28) production by IL-10 during sepsis requires STAT3 but not SOCS3.

Authors:  Markus Bosmann; Norman F Russkamp; Birgit Strobl; Julian Roewe; Liza Balouzian; Florence Pache; Markus P Radsak; Nico van Rooijen; Firas S Zetoune; J Vidya Sarma; Gabriel Núñez; Mathias Müller; Peter J Murray; Peter A Ward
Journal:  J Immunol       Date:  2014-10-27       Impact factor: 5.422

2.  TLR7 Expression Aggravates Invasive Pulmonary Aspergillosis by Suppressing Anti-Aspergillus Immunity of Macrophages.

Authors:  Banglao Xu; Qin Luo; Yi Gong; Jiaxi Li; Ju Cao
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

3.  Staphylococcus aureus-induced immunosuppression mediated by IL-10 and IL-27 facilitates nasal colonisation.

Authors:  Alanna M Kelly; John M Leech; Sarah L Doyle; Rachel M McLoughlin
Journal:  PLoS Pathog       Date:  2022-07-01       Impact factor: 7.464

4.  The effects of CD14 and IL-27 on induction of endotoxin tolerance in human monocytes and macrophages.

Authors:  Carlene Petes; Victoria Mintsopoulos; Renée L Finnen; Bruce W Banfield; Katrina Gee
Journal:  J Biol Chem       Date:  2018-09-21       Impact factor: 5.157

5.  Interleukin-27 Is a Potential Rescue Therapy for Acute Severe Colitis Through Interleukin-10-Dependent, T-Cell-Independent Attenuation of Colonic Mucosal Innate Immune Responses.

Authors:  Mairi H McLean; Caroline Andrews; Miranda L Hanson; Walter A Baseler; Miriam R Anver; Emilee Senkevitch; Aleksandra K Staniszewska; Christopher Smith; Luke C Davies; Julie Hixon; Wenqeng Li; Wei Shen; Lothar Steidler; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2017-11       Impact factor: 5.325

6.  BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis.

Authors:  Byron Brook; Danny J Harbeson; Casey P Shannon; Bing Cai; Daniel He; Rym Ben-Othman; Freddy Francis; Joe Huang; Natallia Varankovich; Aaron Liu; Winnie Bao; Morten Bjerregaard-Andersen; Frederik Schaltz-Buchholzer; Lilica Sanca; Christian N Golding; Kristina Lindberg Larsen; Ofer Levy; Beate Kampmann; Rusung Tan; Adrian Charles; James L Wynn; Frank Shann; Peter Aaby; Christine S Benn; Scott J Tebbutt; Tobias R Kollmann; Nelly Amenyogbe
Journal:  Sci Transl Med       Date:  2020-05-06       Impact factor: 17.956

7.  Cigarette Smoke Induction of Interleukin-27/WSX-1 Regulates the Differentiation of Th1 and Th17 Cells in a Smoking Mouse Model of Emphysema.

Authors:  Shi-Lin Qiu; Min-Chao Duan; Yi Liang; Hai-Juan Tang; Guang-Nan Liu; Liang-Ming Zhang; Chao-Mian Yang
Journal:  Front Immunol       Date:  2016-12-05       Impact factor: 7.561

Review 8.  Target the Host, Kill the Bug; Targeting Host Respiratory Immunosuppressive Responses as a Novel Strategy to Improve Bacterial Clearance During Lung Infection.

Authors:  Alanna M Kelly; Rachel M McLoughlin
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

9.  The interleukin-27 -964A>G polymorphism enhances sepsis-induced inflammatory responses and confers susceptibility to the development of sepsis.

Authors:  Junbing He; Quanfu Zhang; Wenying Zhang; Feng Chen; Tian Zhao; Yao Lin; Jia Li; Yansong Liu; Yuchun Liu; Yiming Shao
Journal:  Crit Care       Date:  2018-09-30       Impact factor: 9.097

Review 10.  Interleukin-27 and Its Diverse Effects on Bacterial Infections.

Authors:  Yugo Morita; Elysia A Masters; Edward M Schwarz; Gowrishankar Muthukrishnan
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.